Hyperparathyroidism Clinical Trials
2 recruiting trials for Hyperparathyroidism. Eligibility criteria explained in plain English.
TrialFinderData lists 2 Hyperparathyroidism clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Research is led by Bo Wang,MD (1), Bettina Mittendorfer (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is PTFinder Dual-Channel NIR Autofluorescence Imaging System (device, 1 trial), followed by Offline Machine-Learning Algorithm (PTFinder-AI Beta), Endothelial cell collection.
Track Hyperparathyroidism trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
Dual-Channel Near-Infrared Autofluorescence Imaging and AI Analysis to Locate Parathyroid Glands (PTFinder)
This study tests PTFinder, a dual-camera system that makes parathyroid glands glow on screen by capturing their natural near-infrared autofluorescence. After a thyroid or...
Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine,...
The purpose of this research study is to validate (check the accuracy of) laboratory assays, intravenous catheter insertion, and equipment or devices and their reproducibility,...
Explore Other Conditions
Frequently Asked Questions
There are currently 2 clinical trials for Hyperparathyroidism, with 2 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Hyperparathyroidism, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Hyperparathyroidism, representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.